No­var­tis’ Leqvio cuts LDL lev­els by 50% over three years: #ESC23

No­var­tis said that 78.4% of pa­tients in a Phase III met a pre-spec­i­fied low-den­si­ty lipopro­tein cho­les­terol tar­get af­ter tak­ing the siR­NA cho­les­terol drug Leqvio for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER